13 completed, 2 recruiting, 2 terminated, 2 unknown. 20 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 20 | Completed 13, Recruiting 2, Terminated 2, Unknown 2, Withdrawn 1 |
| Phase 2 | 5 | Completed 3, Recruiting 1, Terminated 1 |
Follow Speech Disorders: new trials by email Literature Review of Speech Disorders trials Research Report on Speech Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dopamine and Sensorimotor Function in Stuttering Aripiprazole 10 MG, Placebo - Stuttering, Adult | Phase 1 | Recruiting | University of California, San Francisco | 25 | 2025-09-30 | 2026-08-19 |
| A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN) Intrathalamic AAV.PGRN administration, Intrathalamic AVB-101 - Frontotemporal Dementia, FTD | Phase 1 / Phase 2 | Recruiting | AviadoBio Ltd | 18 | 2023-08-30 | 2026-08-13 |
| Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S QBS10072S - Astrocytoma, Brain Cancer | Phase 1 | Completed | Quadriga Biosciences, Inc. | 15 | 2020-07-20 | 2023-01-18 |
| Proof-of-concept Study of LUNA Intervention in Aphasia LUNA - Aphasia, Stroke | Phase 1 | Completed | City, University of London | 28 | 2020-06-14 | 2023-05-06 |
| Intranasal Inhalations of M2 Macrophage Soluble Factors in Children With Developmental Speech Disorders Bioactive Factors, Produced by M2 Type Macrophages (M2-BFs). - Language Delay, Language; Developmental Disorder, Expressive | Phase 1 / Phase 2 | Completed | Russian Academy of Medical Sciences | 14 | 2020-02-01 | 2022-05-02 |
| BIIB092 in Primary Tauopathies: CBS, nfvPPA, sMAPT, and TES BIIB092, Placebo - Primary Tauopathies, Corticobasal Degeneration Syndrome | Phase 1 | Terminated | University of California, San Francisco | 22 | 2018-09-12 | 2019-12-19 |
| A 24-month Phase 1 Pilot Study of AADvac1 in Patients With Non Fluent Primary Progressive Aphasia AADvac1 40 µg, AADvac1 160 µg - Primary Progressive Nonfluent Aphasia | Phase 1 | Unknown | Axon Neuroscience SE | 33 | 2017-07-31 | 2019-11-14 |
| Assessment of Hyperphosphorylated Tau PET Binding in Primary Progressive Aphasia and Frontotemporal Dementia F-18 AV 1451 - Primary Progressive Aphasia, Behavioral Variant of Frontotemporal Dementia | Phase 1 | Completed | Mayo Clinic | 81 | 2016-07-01 | 2025-11-21 |
| Evaluating Anodal tDCS Preceding Aphasia Therapy transcranial direct current stimulation - Stroke, Aphasia | Phase 1 / Phase 2 | Terminated | Northwell Health | 15 | 2014-09-01 | 2021-04-05 |
| Brief Behavioral Treatment for Anxiety in Young Children Parent-Led Exposure Therapy, Treatment As Usual - Obsessive-compulsive Disorder, Social Phobia | Phase 1 / Phase 2 | Completed | University of South Florida | 58 | 2014-01-01 | 2016-10-06 |
| Amyloid-related Imaging Abnormalities (Microbleeds) in Atypical AD C-11 PiB - Atypical Alzheimers Disease, Logopenic Variant of Primary Progressive Aphasia (LPA) | Phase 1 | Completed | Mayo Clinic | 27 | 2012-11-01 | 2015-12-21 |
| The Effects of Tactile Speech Feedback on Stuttering Frequency Tactile Stimulation - Stuttering | Phase 1 | Withdrawn | University of Mississippi, Oxford | 2011-03-01 | 2014-05-12 | |
| Transcranial Direct Current Stimulation and Aphasia Language Therapy Transcranial Direct Current Stimulation - Cathodal stimulation, Transcranial Direct Current Stimulation - Anodal stimulation, Transcranial Direct Current Stimulation - Sham stimulation - Nonfluent Aphasia, Stroke | Phase 1 | Completed | Shirley Ryan AbilityLab | 12 | 2010-03-01 | 2017-05-15 |
| PiB PET Scanning in Speech and Language Based Dementias C-11 PiB, F-18 FDG - PPA, Primary Progressive Aphasia | Phase 1 | Completed | Mayo Clinic | 168 | 2010-03-01 | 2015-12-22 |
| Davunetide (AL-108) in Predicted Tauopathies - Pilot Study davunetide (AL-108, NAP), Placebo nasal spray - Predicted Tauopathies, Including, Progressive Supranuclear Palsy | Phase 1 | Completed | University of California, San Francisco | 12 | 2010-01-01 | 2019-04-05 |
| Treating Intention In Aphasia: Neuroplastic Substrates Word-finding with intention component, Word-finding with no intention component - Aphasia, Cerebrovascular Accident | Phase 1 / Phase 2 | Completed | University of Florida | 14 | 2007-03-01 | 2012-05-03 |
| Improve Speech Using an In-the-ear Device in Parkinson's Disease SpeechEasy Model ITC - Parkinson's Disease, Dysarthria | Phase 1 | Completed | Rush University Medical Center | 40 | 2006-06-01 | 2013-01-18 |
| Levetiracetam (Keppra) to Improve Chronic Aphasia in Post-stroke Patients. Wait first, then levetiracetam, Levetiracetam first, then wait - Aphasia, Stroke | Phase 1 | Unknown | Kessler Foundation | 50 | 2005-09-01 | 2021-02-17 |
| Assessment of Cortical Stimulation Combined With Rehabilitation to Enhance Recovery in Broca's Aphasia. Cortical Electrical Stimulation - Stroke, Broca's Aphasia | Phase 1 | Completed | Northstar Neuroscience | 8 | 2004-12-01 | 2007-09-21 |
| Transcranial Magnetic Stimulation to Improve Speech in Aphasia Transcranial Magnetic Stimulation, Repetitive - Aphasia, Cerebrovascular Stroke | Phase 1 | Completed | Boston University | 63 | 2002-07-01 | 2017-01-31 |
Aphasia (8) · Stroke (7) · Aphasia, Primary Progressive (4) · Primary Progressive Nonfluent Aphasia (4) · Aphasia, Broca (3) · Frontotemporal Dementia (3) · Language (3) · Pick Disease of the Brain (3) · Apraxias (2) · Ischemic Stroke (2) · Speech (2) · Stuttering (2) · Anorexia (1) · Anxiety Disorders (1)
Nervous System Diseases (20) · Neurobehavioral Manifestations (20) · Neurologic Manifestations (20) · Pathological Conditions, Signs and Symptoms (20) · Signs and Symptoms (20) · Communication Disorders (19) · Language Disorders (19) · Brain Diseases (15) · Central Nervous System Diseases (15) · Mental Disorders (9) · Cardiovascular Diseases (7) · Cerebrovascular Disorders (7) · Vascular Diseases (7) · Aphasia (6)
2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole (2) · Transcranial Direct Current Stimulation (2) · AADvac1 (1) · Aripiprazole (1) · Levetiracetam (1) · Therapeutics (1) · Transcranial Magnetic Stimulation (1) · davunetide (1) · gosuranemab (1)
Mayo Clinic (3) · University of California, San Francisco (3) · AviadoBio Ltd (1) · Axon Neuroscience SE (1) · Boston University (1) · City, University of London (1) · Kessler Foundation (1) · Northstar Neuroscience (1) · Northwell Health (1) · Quadriga Biosciences, Inc. (1) · Rush University Medical Center (1) · Russian Academy of Medical Sciences (1) · Shirley Ryan AbilityLab (1) · University of Florida (1) · University of Mississippi, Oxford (1)
United States (16) · United Kingdom (2) · Australia (1) · Belgium (1) · Canada (1) · Germany (1) · Italy (1) · Netherlands (1) · Poland (1) · Russia (1) · Spain (1) · Sweden (1)
A.M. Barrett, MD (1) · Adam Boxer, MD, PhD (1) · Adam L. Boxer, M.D., Ph.D. (1) · Alexander A Ostanin, MD, PhD (1) · Alvaro Pascual-Leone, M.D., Ph.D. (1) · Bruce Crosson, PhD (1) · Dwight E Waddell, Ph.D. (1) · Elena R Chernykh, MD, PhD (1) · Emily Wang, PHD (1) · H B Coslett, M.D. (1) · Jennifer Whitwell, PhD (1) · John Houde, PhD (1) · Keith A Josephs, M.D. (1) · Keith A Josephs, M.D. MST, MSc (1) · Leo Verhagen, MD, PHD (1)
PMID 15118944, PMID 15766771, PMID 16006338, PMID 19425468, PMID 19695692, PMID 20159655, PMID 20299861, PMID 21794852, PMID 21864891, PMID 23280015, PMID 26704258, PMID 29256908, PMID 38875279
2017 (1), 2023 (1), R01DC005672 (1), R01DC007387 (1), R21DC009876 (1), R21DC021557 (1), R21NS094684 (1)